21165 ⎘
Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA; Animal cells expressing foreign proteins
Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
#602NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same
#603Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
#604Compositions and methods for treating cancer with anti-CD22 immunotherapy
#605Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
#606Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
#607Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
#608Compositions and methods for treating cancer with anti-CD19 immunotherapy
#609Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
#610HIV pre-immunization and immunotherapy
#611Recombinant NK cells expressing co-stimulatory molecules
#612Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
#613CHIMERIC ANTIGEN RECEPTORS (CAR) AND METHODS FOR MAKING AND USING THE SAME
#614Compositions and methods for treating cancer with anti-CD33 immunotherapy
#615Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
#616Micro-RNA-155 enhances the efficacy of dendritic cell vaccine for cancer
#617Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
#618Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
#619Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
#620Immune cells expressing engineered antigen receptors
#621BCMA chimeric antigen receptors
#622GENE THERAPY
#623Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
#624Protective Chimeric Antigen Receptor Stem Cell Gene Therapy for Viral Infection
#625CHIMERIC ENGULFMENT RECEPTOR MOLECULES
#626CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
#627Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
#628Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
#629Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
#630Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
#631METHODS FOR INDUCING SELECTIVE APOPTOSIS
#632Variant survivin vaccine for treatment of myeloma
#633DNA vector and transformed tumor cell vaccines
#634BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
#635Claudin-6-specific immunoreceptors and t cell epitopes
#636BCMA chimeric antigen receptors
#637BCMA chimeric antigen receptors
#638BCMA chimeric antigen receptors
#639BCMA chimeric antigen receptors
#640Car+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
#641Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer
#642Fractal combination therapy
#643Coordinating gene expression using RNA destabilizing elements
#644Materials and methods for engineering cells and uses thereof in immuno-oncology
#645Materials and methods for engineering cells and uses thereof in immuno-oncology
#646Engineered multi-component system for identification and characterisation of T-cell receptors and T-cell antigens
#647Compositions and methods for modified B cells expressing reassigned biological agents
#648Coordinating gene expression using RNA destabilizing elements
#649DENDRITIC CELL PREPARATIONS, COMPOSITIONS THEREOF AND METHODS OF USING SAME
#650Reducing immune tolerance induced by PD-L1
#651Antibody agents specific for human CD19 and uses thereof
#652Materials and methods for engineering cells and uses thereof in immuno-oncology
#653Materials and methods for engineering cells and uses thereof in immuno-oncology
#654Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
#655Systemic targeting of inflammatory sites and enhanced immunomodulatory function by introducing the chimeric antigen receptor (CAR) into mesenchymal stem cells for inflammatory and autoimmune diseases
#656COMBINATION THERAPY OF A T CELL-BASED THERAPY AND A BTK INHIBITOR
#657CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
#658Chimeric antigen receptors that bind to SSEA4 and uses thereof
#659Complexes of IL-15 and IL-15Ralpha and uses thereof
#660Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
#661Methods and compositions related to toxicity associated with cell therapy
#662Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
#663Vectors and methods for long-term immune evasion to prolong transplant viability
#664BAFF-R targeted chimeric antigen receptor-modified t-cells and uses thereof
#665Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
#666Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
#667Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
#668Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
#669Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
#670Drug regulated transgene expression
#671Coordinating gene expression using RNA destabilizing elements
#672Activated CD26-high immune cells and CD26-negative immune cells and uses thereof
#673Chimeric antigen receptors targeting B-cell maturation antigen
#674Compositions and methods for treating cancer with DuoCARs
#675Cereblon-based heterodimerizable chimeric antigen receptors
#676Chimeric antigen receptor for efficient selective proliferation in vitro and uses thereof
#677Chimeric antigen receptors targeting CD70
#678Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use
#679AUTOLOGOUS CELLS FOR IMMUNIZATION OF CHICKENS
#680CTLA-4-targeting trans-splicing ribozyme for delivery of chimeric antigen receptor, and use thereof
#681FLT3-specific chimeric antigen receptors and methods using same
#682HPV-specific binding molecules
#683Cell-based neoantigen vaccines and uses thereof
#684Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
#685Adoptive t-cell therapy
#686HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY
#687Specific Chimeric Antigen Receptor T Cells Targeting to CD47, Preparation Method and Application Thereof
#688Use of specific regulatory T-cells to induce immune tolerance
#689Genetically-modified cells and method for producing same
#690HIV pre-immunization and immunotherapy
#691GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#692T cell compositions
#693Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same
#694Biologically relevant orthogonal cytokine/receptor pairs
#695Compositions and methods for inhibiting T cell exhaustion
#696Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
#697TUMOR VACCINE
#698T cells for expression of chimeric antigen receptors and other receptors
#699Optimized PNE-based chimeric receptor T cell switches and uses thereof
#700Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
#701Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)
#702Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
#703Genetically modified T lymphocytes
#704Ig-pCONSENSUS GENE VACCINATION PROTECTS FROM ANTIBODY-DEPENDENT IMMUNE PATHOLOGY IN AUTOIMMUNE DISEASE
#705CD-38 directed chimeric antigen receptor constructs
#706COMPOSITIONS AND METHODS FOR IMPROVED NK CELL THERAPIES
#707COMBINATION THERAPY COMPRISING AN INFLAMMATORY IMMUNOCYTOKINE AND A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL
#708HLA-G AS A NOVEL TARGET FOR CAR T-CELL IMMUNOTHERAPY
#709ENGAGER CELLS FOR IMMUNOTHERAPY
#710Compositions and methods for tumor transduction
#711Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1
#712Compositions and methods for CD20 immunotherapy
#713Compositions and methods for treating cancer with anti-CD19 immunotherapy
#714T cell modification and use thereof
#715Compositions and methods for treating cancer with anti-CD22 immunotherapy
#716Use of car and bite technology coupled with an ScFv from an antibody against human thymidine kinase 1 to specifically target tumors
#717Methods and compositions for car T cell therapy
#718Anti-Sialyl Tn chimeric antigen receptors
#719M971 chimeric antigen receptors
#720Compositions and methods for treating cancer with DuoCARs
#721IMMUNE-CHECKPOINT INHIBITORS FOR USE IN THE TREATMENT OF BLOOD-BORNE CANCERS
#722Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors
#723Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors
#724High avidity HPV T-cell receptors
#725Binding members to PD-L1
#726MODIFIED CELLS FOR IMMUNOTHERAPY
#727Antibody against glypican-3 and application thereof
#728Whole-cell cancer vaccines and methods for selection thereof
#729T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
#730T CELL RECEPTOR-DEFICIENT CHIMERIC ANTIGEN RECEPTOR T-CELLS AND METHODS OF USE THEREOF
#731ENGINEERED CELLS & METHODS
#732ENGINEERED MAMMALIAN CELLS FOR CANCER THERAPY
#733METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF
#734MESENCHYMAL STEM CELLS TO ENHANCE ANTI-TUMOR ACTIVITY OF IMMUNOTHERAPY
#735METHODS AND COMPOSITIONS FOR T-CELL IMMUNOTHERAPY
#736T CELL RECEPTORS
#737Methods for selectively expanding and enriching cells transduced with chimeric antigen receptors and treating HIV infection
#738Chimeric T cell
#739Methods for inducing migration by dendritic cells and an immune response
#740GM-CSF and IL-4 conjugates, compositions, and methods related thereto
#741ADHERENT CANCER CELL LINE EXPRESSING A HEMATOLOGICAL TUMOR ANTIGEN
#742Conditionally active chimeric antigen receptors for modified t-cells
#743Targeted protein degradation
#744T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complex
#745Compositions and methods for use of recombinant T cell receptors for direct recognition of tumor antigen
#746Vector co-expressing vaccine and costimulatory molecules
#747Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
#748HIGH AFFINITY NY-ESO T CELL RECEPTORS
#749Antigen-specific T cells for inducing immune tolerance
#750Chimeric antigen receptor targeting human NKG2DL and methods of preparing said receptor and pharmaceutical composition
#751Methods and compositions for reducing the immunogenicity of chimeric notch receptors
#752Vector co-expressing vaccine and costimulatory molecules
#753Compositions and Methods for Treatment of Her2 Positive Metastatic Breast Cancer
#754Cancer antigen targets and uses thereof
#755Chimeric antigen receptor cell preparation and uses thereof
#756Cell
#757Methods and compositions relating to chimeric antigen receptors
#758Composition and therapeutic anti-tumour vaccine
#759Conditionally active chimeric antigen receptors for modified T-cells
#760Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
#761Method of manufacturing dual-specific T-cells for use in cancer immunotherapy
#762Engineered Cells Expressing Multiple Immunomodulators and Uses Thereof
#763Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory T lymphocytes
#764Codon-optimized lentiviral vector for stem cell reprogramming
#765Chimeric antigen receptors targeting HER2
#766Modified natural killer cells and natural killer cell lines having increased cytotoxicity
#767Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
#768NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
#769T cell receptor-deficient T cell compositions
#770Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
#771Altering gene expression in modified T cells and uses thereof
#772Treatment of cancer using a CD123 chimeric antigen receptor
#773Chimeric receptor with ligand binding exodomain and cytokine and T cell signalling endodomains
#774Method for prevention or treatment of one or more of diseases relevant to the protein in the protein-cell conjugate, malignant tumors, infectious diseases caused by pathogenic microorganisms and autoimmune diseases
#775Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
#776Targeted cancer therapy
#777METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTOR ADAPTERS
#778Method for enrichment and expansion of virus antigen-specific T cells
#779TCR AND USES THEREOF
#780T cells with increased immunosuppression resistance
#781T cell receptor-deficient T cell compositions
#782Anti-podocalyxin antibodies and methods of using the same
#783Method and compositions for cellular immunotherapy
#784Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells
#785Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients
#786CHIMERIC ANTIGEN RECEPTOR, REGULATORY CELLS AND METHODS OF USE
#787Method for preparing genetically-modified T cells which express chimeric antigen receptor
#788Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
#789Methods to protect transplanted tissue from rejection
#790ANTIGEN RECEPTORS AND USES THEREOF
#791Combination of immune effector cells specific for a target antigen and hematopoietic cells that express the target antigen in an altered form
#792Compositions and methods for treating cancer with anti-CD33 immunotherapy
#793CHIMERIC ANTIGEN RECEPTORS FOR MELANOMA AND USES THEREOF
#794MODIFIED T LYMPHOCYTES HAVING IMPROVED SPECIFICITY
#795METHODS FOR INDUCING SELECTIVE APOPTOSIS
#796NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same
#797Methods of increasing T cell immune response in the treatment of cancer
#798Methods and compositions for gene editing in hematopoietic stem cells
#799Genetically engineered drug resistant T cells and methods of using the same
#800Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
#801Methods for inducing selective apoptosis
#802Methods and compositions for cells expressing a chimeric intracellular signaling molecule
#803Quality of immunological synapse predicts effectiveness of chimeric antigen receptor (CAR) T cells
#804Antibodies to MUC16 and methods of use thereof
#805VEGFR-2 car immune cells to treat cancers
#806Antibody
#807Fusion molecule based on TAA variant
#808Biologically relevant orthogonal cytokine/receptor pairs
#809TRANSINFECTED LYMPHOCYTES FOR ANTI-TUMOR THERAPY
#810Compositions and methods for modified B cells expressing reassigned biological agents
#811BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLS
#812Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
#813Modified natural killer cells and natural killer cell lines having increased cytotoxicity
#814Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
#815Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer
#816Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
#817HIV pre-immunization and immunotherapy
#818Modified NK-92 cells for treating cancer
#819GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy
#820Method of treating multiple myeloma using natural killer cells expressing a chimeric antigen receptor for CD38
#821Compositions, methods and kits for eliciting an immune response
#822TUMORS EXPRESSING IgG1 Fc INDUCE ROBUST CD8 T CELL RESPONSES
#823Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
#824T cell receptor-like antibodies specific for a PRAME peptide
#825Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
#826Chimeric antigen receptors and uses thereof
#827Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
#828Enhancing the effect of car-engineered T cells by means of nucleic acid vaccination
#829Antibody agents specific for human CD19 and uses thereof
#830ENHANCING THE T-CELL STIMULATORY CAPACITY OF HUMAN ANTIGEN PRESENTING CELLS IN VITRO AND IN VIVO AND ITS USE IN VACCINATION
#831Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
#832Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
#833Vectors and methods for long-term immune evasion to prolong transplant viability
#834FLT3 directed car cells for immunotherapy
#835Double mutant survivin vaccine
#836EGFR-directed car therapy for glioblastoma
#837Humanized anti-MUC1* antibodies
#838Multipotent Adult Stem Cells and Methods for Isolation
#839NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR
#840OPTIMIZED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF
#841COMPOSITION AND METHODS OF GENOME EDITING OF B-CELLS
#842COMPOSITIONS TO DISRUPT PROTEIN KINASE A ANCHORING AND USES THEREOF
#843Protein-based T-cell receptor knockdown
#844DNA vector and transformed tumor cell vaccines
#845BCMA chimeric antigen receptors
#846Whole expressed cell as antigen carrier, and use thereof in preparing vaccine or diagnostic agent, and screening monoclonal antibodies
#847CAR-T LYMPHOCYTES ENGINEERED TO HOME TO LYMPH NODE B CELL ZONE, SKIN, OR GASTROINTESTINAL TRACT
#848Combination immunotherapy for treating cancer
#849METHOD FOR ANTIGEN LOADING OF DENDRITIC CELLS AND VACCINE
#850HIGH AFFINITY NY-ESO T CELL RECEPTORS
#851Chimeric antigen receptors (CARs), targeting hematologic malignancies, compositions and methods of use thereof
#852Treatment of cancer using a CD33 chimeric antigen receptor
#853Inhibitory chimeric antigen receptors
#854CHIMERIC ANTIGEN RECEPTOR COMBINATION THERAPY FOR TREATING TUMORS
#855METHOD OF TREATING TUMORS WITH NK AND NKT CELLS EXPRESSING ANTI-SSEA4 CHIMERIC ANTIGEN RECEPTORS
#856ANTI-SSEA4 CHIMERIC ANTIGEN RECEPTORS AND THEIR USE FOR TREATING CANCER
#857Engineering and delivery of therapeutic compositions of freshly isolated cells
#858Bi-specific chimeric antigen receptor and uses thereof
#859Engineered T cells and uses therefor
#860Chimeric antigen receptor signalling system comprising heterodimerization domains
#861Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy
#862Method and compositions for cellular immunotherapy
#863Methods for enhancing efficacy of therapeutic immune cells
#864CELL FOR USE IN IMMUNOTHERAPY WHICH CONTAINS MODIFIED NUCLEIC ACID CONSTRUCT ENCODING WILMS TUMOR GENE PRODUCT OR FRAGMENT THEREOF, METHOD FOR PRODUCING SAID CELL, AND SAID NUCLEIC ACID CONSTRUCT
#865ANTI-HSP70 SPECIFIC CHIMERIC ANTIGEN RECEPTORS (CARS) FOR CANCER IMMUNOTHERAPY
#866Enhanced affinity T cell receptors and methods for making the same
#867CS1 targeted chimeric antigen receptor-modified T cells
#868Methods and compositions for transducing lymphocytes and regulating the activity thereof
#869Compositions and methods for improved car-T cell therapies
#870Adherent cancer cell line expressing a hematological tumor antigen
#871ADJUVANTS USEFUL FOR STIMULATION OF IMMUNITY TO TUMOR ENDOTHELIAL CELLS
#872Methods and compositions relating to anti-CCR7 antigen binding proteins
#873TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR
#874Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
#875Treatment of cancer using GFR α-4 chimeric antigen receptor
#876Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
#877CD4 T cells provide antibody access to immunoprivileged tissue
#878Use of antibodies for enrichment of engineered T cells with exogenous immune receptors and antibodies for use in depletion of engineered T cells
#879Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells
#880Method for establishing pluripotent stem cells bearing genes encoding antigen specific T cell receptor
#881CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHOD FOR ISOLATION AND USES
#882CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHOD FOR ISOLATION AND USES
#883CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS
#884Altering gene expression in modified T cells and uses thereof
#885ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy
#886Chimeric antigen receptor specific for SSEA4 antigen
#887Chimeric antigen and T cell receptors and methods of use
#888Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof
#889EX VIVO DEVELOPMENT, EXPANSION AND IN VIVO ANALYSIS OF A NOVEL LINEAGE OF DENDRITIC CELLS
#890Transgene genetic tags and methods of use
#891Engineering and delivery of therapeutic compositions of freshly isolated cells
#892T-cell receptor-deficient T cell compositions
#893Artificial nucleic acid molecules for improved protein or peptide expression
#894Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
#895Combination immunotherapy approach for treatment of cancer
#896Multi-indication mRNA cancer immunotherapy
#897TUMOR IMMUNITY
#898METHODS OF ISOLATING T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION
#899INNATE IMMUNE SYSTEM MODIFICATION FOR ANTICANCER THERAPY
#900Engineered cells for adoptive cell therapy